One of the most important prob lems during cardiac surgery is the prevention and treatment of hyper tension, occurring in 40-60% of the patients following coronary artery bypass surgery (CABS). Hyperten sion should be avoided to prevent myocardial damage, neurologic com plications, increased blood loss, and premature graft closure due to inti mal damage. During and following cardiac surgery hypertension is rou tinely treated with vasodilating agents, which generally induce reflex tachycardia and increased intrapul monary shunting.
The results obtained with ketan serin, a specific S 2-serotonergic re ceptor blocker with alpha1-adrener gic receptor blocking properties, in the prevention and treatment of hy pertension in patients undergoing cardiac surgery, are presented. Ke tanserin effectively lowers blood pressure by decreasing systemic vas cular resistance but does not com pletely prevent perioperative and postoperative hypertension when ad ministered as a continuous infusion from the start of anesthesia. In con trast to sodium nitroprusside, ketan serin does not induce reflex tachycar dia in the treatment of postoperative systemic hypertension following CABS. The compound improves di uresis and perfusion of the skin pe rioperatively. Ketanserin is devoid of rebound phenomena after its admin istration is stopped. It is postulated that the antihypertensive effect of ke tanserin can be explained by its prop erty of simultaneously blocking al pha 1-adrenergic and S2-serotonergic receptors.
Get full access to this article
View all access options for this article.
References
1.
Estafanous FG , Tarazi RC: Systemic arterial hypertension associated with cardiac surgery. Am J Cardiol46:685-694, 1980.
2.
Estafanous FG , Tarazi RC, Viljoen JF, et al: Systemic hypertension following myocardial revascularization. Am Heart J85:732-738, 1973.
3.
Roberts AJ, Niarchos AP, Subramanian VA, et al: Systemic hypertension associated with coronary artery surgery. Predisposing factors, hemodynamic characteristics, humoral profile, and treatment . J Thorac Cardiovasc Surg74:846-859, 1977.
4.
Forbes AM, Dally FG: Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. Br J Anaesth42:618-624, 1970.
5.
Wycoff CO: Endotracheal intubation: Effects on blood pressure and pulse rate. Anesthesiology21:153-158, 1960.
6.
Fox EJ, Sklar GS, Hill CH, et al: Complications related to the pressor response to endotracheal intubation. Anesthesiology47:524-525, 1977.
7.
Low JM, Harvey JT, Prys-Roberts C.: Studies on anaesthesia in relation to hypertension. Br J Anaesth58:471-477, 1986.
8.
Balasarawathi K., Glisson SN, El-Etr AA, et al: Serum epinephrine and norepinephrine during valve replacement and aorto-coronary bypass. Can Anaesth Soc J29:533-538, 1982.
9.
Hine IP, Wood WG, Mainwaring-Burton RW, et al: The adrenergic response to surgery involving cardiopulmonary bypass, as measured by plasma and urinary catecholamine concentrations. Br J Anaesth48:355-363, 1976.
10.
Arnett EL, Watts DT: Catecholamine excretion in men exposed to cold. J Appl Physiol15:499-500, 1960.
11.
Chernow B., Lake CR, Zaritsky A., et al: Sympathetic nervous system switch off with severe hypothermia . Crit Care Med11:677-680, 1983.
12.
Landymore RW , Murphy DA, Kinley CE, et al: Does pulsatile flow influence the incidence of postoperative hypertension?Ann Thorac Surg28:261-265, 1979.
13.
Taylor KM, Morton IJ, Brown JJ, et al: Hypertension and renin-angiotensin system following open heart surgery. J Thorac Cardiovasc Surg74:840-845, 1977.
14.
Solis RT, Beall Jr AC, Noon GP, et al: Platelet aggregation: Effects of cardiopulmonary bypass. Chest67:558-564, 1975.
15.
Faymonville ME, Deby-Dupont G., Larbuisson R., et al: Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans . J Thorac Cardiovasc Surg91:858-866, 1986.
16.
Replogle R. , Levy M., DeWall RA, et al: Catecholamine and serotonin response to cardiopulmonary bypass. J Thorac Cardiovasc Surg44:638-648, 1962.
17.
Swank RL, Hissen W., Bergentz SE, et al: 5-Hydroxytryptamine and aggregation of blood elements after trauma. Surg Gynecol Obstet119:779-783, 1964.
18.
Cooper TJ, Clutton-Brock TH, Jones S., et al: Factors relating to the development of hypertension after cardiopulmonary bypass. Br Heart J54:91-105, 1985.
19.
Moffitt EA, Sethna DH: The coronary circulation and myocardial oxygenation in coronary artery disease: Effects of anesthesia. Anesth Analg65:395-410, 1986.
20.
Slogoff S., Keats AS: Does perioperative myocardial ischemia lead to postoperative myocardial infarction?Anesthesiology62:107-114, 1985.
21.
Fremes SE, Weisel RD, Baird RJ, et al: Effects of postoperative hypertension and its treatment. J Thorac Cardiovasc Surg86:47-56, 1983.
22.
Kolkka R., Hilberman M.: Neurologic dysfunction following cardiac operation with low-flow, low-pressure cardiopulmonary bypass. J Thorac Cardiovasc Surg79:432, 1980.
23.
Brody WR, Kosek JC, Angell WW: Changes in vein grafts following aorto-coronary bypass induced by pressure and ischemia. J Thorac Cardiovasc Surg64:847, 1972.
24.
Stinson EB, Holloway EL, Derby G., et al: Comparative hemodynamic responses to chlorpromazine, nitroprusside, nitroglycerin, and trimethaphan immediately after open-heart operations. Circulation51 (suppl 1):26-33, 1975.
Kaplan JA, Finlayson DC, Woodward S.: Vasodilator therapy after cardiac surgery: A review of the efficacy and toxicity of nitroglycerin and nitroprusside. Can Anesth Soc J27:254, 1980.
27.
Berthelsen P., Haxholdt Ost, Husum B., et al: PEEP reverses nitroglycerin-induced hypoxemia following coronary artery bypass surgery. Acta Anaesthesiol Scand30:243-246, 1986.
28.
Wenting GJ, Man in 't Veld AJ, Woittiez AJ, et al: Haemodynamic effects of ketanserin, a new selective 5-hydroxytryptamine (serotonin) receptor antagonist, in essential hypertension. Clin Sci62 (suppl 8):435-438, 1982.
29.
Van der Starre Pja, Scheijgrond HW, Reneman RS, et al: The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery. Anesth Analg62:63-69, 1983.
30.
Boumameaux HM, Hellemans H., Verhaeghe R., et al: Ketanserin in secondary Raynaud's phenomenon. J Cardiovasc Pharmacol6:975-976, 1984.
31.
Weiner CP, Socol ML, Vaisrub N.: Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist. Am J Obstet Cynecol149:496-500, 1984.
32.
Huval WV, Mathieson MA, Stemp LI, et al: Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism. Ann Surg197:220-225, 1983.
33.
Thomson JA, Wei EP, Kontos HA: Inhibition by ketanserin of serotonin induced cerebral arteriolar constriction . Stroke15:1021-1024, 1984 .
34.
Wenting GJ, Woittiez AJ, Man in 't Veld AJ, et al: 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension6:100-109, 1984.
35.
Bolt GR, Saxena PR: Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit . Hypertension7:499-506, 1985.
36.
Reimann IW, Frolich JC: Mechanisms of antihypertensive action of ketanserin in man. Br Med J287:381-383, 1983.
37.
Van der Starre Pja, Reneman RS: The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blocking in lowering blood pressure in man. J Cardiovasc Pharmacol11 (suppl 1):S54-61, 1988.
38.
Braunwald E. : Control of myocardial oxygen consumption: Physiologic and clinical considerations. Am J Cardiol27:416-432, 1971.
39.
Smits Jfm, Van Essen H, Tijssen CM, et al: Effects of ketanserin on hemodynamics and baroreflex effects in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol10: 1-8, 1987.
40.
Hilberman M. , Meyers BD, Carrie BJ, et al: Acute renal failure following cardiac surgery. J Cardiovasc Surg77:880-888, 1979.
41.
Garattini S., Valzelli L.: Serotonin. New York: American Elsevier , 1965, p 137.
42.
Blackshear JL, Orlandi C., Hollenberg NK: Serotonin and the renal blood supply: Role of prostaglandins and the 5-HT2-receptor. Kidney Int30:304-310, 1986.
43.
Hardy JF, Boulanger M., Maille JG, et al: Arterial hypertension following coronary artery surgery: Influence of the narcotic agent used for anaesthesia. Can Anaesth Soc J30:370-376, 1983.
44.
Copeland IW , Bentley GA: A possible central action of prazosin and ketanserin to cause hypotension. J Cardiovasc Pharmacol7:822, 1985.
